COLUMBIA, Md., April 6, 2011 /PRNewswire/ -- The Catalysis Foundation for Health has selected the Labmatrix scientific database software system to manage its large-scale international tuberculosis (TB) diagnostic biomarker study that is funded by the Bill & Melinda Gates Foundation.
The Catalysis Foundation for Health (CFH) is a non-profit organization dedicated to developing and delivering high value diagnostic tests for resource-poor settings. This unique multi-year TB study enrolls human subjects from Asian and African sites, where several types of patient biospecimens are gathered at multiple timepoints, processed, and forwarded to North American testing labs for further analysis. Patient specimen data, clinical information and study-related analytical data are all collected and entered into the web-accessible Labmatrix database system.
Through the utilization of Labmatrix, CFH researchers and collaborators in this international TB study are able to centrally manage patient information, track shipment status, as well as study data for thousands of patient biospecimens, and view real-time study results from prebuilt or ad hoc data queries. In addition, data quality, consistency, and privacy are improved via Labmatrix's secure project messaging capabilities, standardized electronic case report forms (eCRF), prescription drug forms, biospecimen and assay result forms, and other workflow-driven information capture mechanisms.
Richard Thayer, Chief Executive, Catalysis Foundation for Health, states, "Labmatrix allows our scientists, investigators, and collaborators to quickly and securely exchange pertinent information across international sites, facilitating both study data management and patient sample management for this complex tuberculosis diagnostic biomarker project."
About Catalysis Foundation for Health
The Catalysis Foundation for Health, founded in 2007 as a 501 (c) (3) private operating foundation, is dedicated to facilitating the development and delivery of diagnostics to address life-threatening infectious diseases and chronic conditions that are endemic in the developing world. The organization may be contacted at www.catalysisfoundation.org
About BioFortis, Inc.
BioFortis, Inc. provides enterprise software solutions within several key application areas including translational research, biobanking, biomarker discovery and clinical research. With the ability to centralize life sciences data sets in a tightly-linked, highly-annotated, and user-friendly manner, the Labmatrix application helps its customers to standardize on best practices in research data management within the biopharmaceutical industry, academia and government research institutions. BioFortis' website address is www.BioFortis.com
SOURCE BioFortis, Inc.